1. Home
  2. PSBD vs GLSI Comparison

PSBD vs GLSI Comparison

Compare PSBD & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PSBD

Palmer Square Capital BDC Inc.

HOLD

Current Price

$10.58

Market Cap

386.6M

Sector

N/A

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$25.96

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSBD
GLSI
Founded
2009
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
386.6M
372.0M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
PSBD
GLSI
Price
$10.58
$25.96
Analyst Decision
Hold
Strong Buy
Analyst Count
8
1
Target Price
$12.50
$50.00
AVG Volume (30 Days)
78.6K
131.8K
Earning Date
05-06-2026
05-19-2026
Dividend Yield
16.22%
N/A
EPS Growth
N/A
N/A
EPS
1.66
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.34
$7.78
52 Week High
$14.96
$34.10

Technical Indicators

Market Signals
Indicator
PSBD
GLSI
Relative Strength Index (RSI) 54.33 53.00
Support Level $10.14 $21.20
Resistance Level $11.12 $30.02
Average True Range (ATR) 0.41 1.87
MACD 0.08 0.38
Stochastic Oscillator 79.87 71.65

Price Performance

Historical Comparison
PSBD
GLSI

About PSBD Palmer Square Capital BDC Inc.

Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: